[Research Report] The Public Opinion Survey on Cancer Genomics and Precision Medicine (March 9, 2022)
date : 3/9/2022
Tags: NCDs, Precision Cancer Medicine, Survey on Healthcare in Japan
![[Research Report] The Public Opinion Survey on Cancer Genomics and Precision Medicine (March 9, 2022)](https://hgpi.org/en/wp-content/uploads/sites/2/cancer-survey2021-top_ENG.jpg)
On March 9, 2022, Health and Global Policy Institute (HGPI) released poll data on public opinion about priorities for policies related to cancer genomics and precision medicine.
The new poll, conducted in October over the internet, asked a series of policy-related questions to a group of 1,000 people, selected without exclusion from a monitor panel of a research firm to be representative of the total population of Japan in terms of age, sex, and region.
Research asked participants about their own or family experience with cancer, and about their awareness and understanding of cancer genomics and precision medicine. Most people said that they had no experience with cancer (77.1%), while 10.4% said that someone in their family has had cancer, 3.4% said they themselves have had cancer, 1.5% said that they and someone in their family have had cancer. The remaining 7.6% stated that they preferred not to answer.
In terms of awareness and understanding, 57.2% said that they had never heard of cancer genomics or precision medicine, while 38.6% said they had heard of these treatments but did not know much about them. Just 4.2% said that they felt they were knowledgeable about this topic.
Results related to awareness and understanding were low regardless of cancer history, with an average of only approximately 55% reporting that they have at least heard of cancer genomics or precision medicine.
Respondents were asked about their prior knowledge of the six characteristics of cancer genomics and precision medicine listed below. Regardless of reported understanding about these topics, prior understanding about genomic testing, the timing of testing, and insurance coverage was particularly low. Even among those who reported having high knowledge of cancer genomics and precision medicine (42 respondents), just 9 (21.4%) answered that they knew all of the following points prior to this survey, further suggesting a need for greater awareness raising on this topic.
1. You can’t receive precision medicine at every hospital
2. Genomic tests investigate dozens to hundreds of genomic changes all at once, providing results about the specific characteristics of the patient’s cancer. This allows research into the best treatment for each patient.
3. Only a portion of genomic tests are covered by insurance
4. Genomic tests can only be done at specific time points
5. The probability of a genomic test being able to identify the best treatment for a patient is limited
6. Genomic tests can determine the possibility of a cancer having genomic causes
HGPI will continue to work to raise awareness and advance policy around cancer genomics and precision medicine through its work on non-communicable diseases.
For more information on this project and recent events on it organized by HGPI, please see here.
日本語
Top Research & Recommendations Posts
- [Policy Recommendations] Developing a National Health and Climate Strategy for Japan (June 26, 2024)
- [Announcement] A Turning Point Towards Building Green Healthcare Systems (June 5, 2024)
- [Research Report] Building a Mental Health Program for Children and Measuring its Effectiveness (June 16, 2022)
- [Research Report] The 2023 Public Opinion Survey on Satisfaction in Healthcare in Japan and Healthcare Applications of Generative AI (January 11, 2024)
- [Research Report] 2019 Survey on Healthcare in Japan
- [Policy Recommendations] Establishing an Integrated Care System for Pain from the Perspectives of People with Lived Experience (March 29, 2024)
- [Research Report] Survey of Japanese Physicians Regarding Climate Change and Health (December 3, 2023)
- [Announcement] Participation in an International Survey on Brain Health for Young People “The Next Generation (NextGen) Brain Health Research Program” (July 1, 2024)
- [Policy Recommendations] Obesity Control Promotion Project 2023 “The Next Steps for Engaging and Cooperating with Patients, Citizens, and Communities for Implements of Obesity Control Measurements” (April 8, 2024)
- [Japanese Version Release] “Call for Actionable Steps in Response to the Rising Threat of Antimicrobial Resistance (AMR)” (July 3, 2024)
Featured Posts
-
2024-07-01
[Registration Open] Meaningful Involvement Promotion Project Online Expert Meeting “Shaping the Future of Health Policy with People with Lived Experience and Citizens” (July 26, 2024)
-
2024-07-17
[Event Report] Non-partisan Diet Member Briefing – 30-minute Health Policy Update: “Towards Overcoming Kidney Disease: Strengthening Measures Against CKD” (June 7, 2024)
-
2024-07-18
[Registration Open] (Hybrid Format) Kidney Disease Control Promotion Project Public Symposium “Establishing Kidney Disease Control Measures with Patient, Citizen, and Community Engagement and Collaboration” (August 28, 2024)
-
2024-07-22
[HGPI Policy Column] No. 44 — From the Planetary Health Policy Project, Part 9 “Connecting Climate Minds: the Intersection of Climate Change and Mental Health”
-
2024-07-23
[Registration Open] (Webinar) HGPI Special Seminar “The Emerging Threat of Antifungal Resistance — Considering Infectious Diseases Caused by Mold and Measures to Combat Drug Resistance” (August 23, 2024)